{"protocolSection":{"identificationModule":{"nctId":"NCT04621357","orgStudyIdInfo":{"id":"2017_70"},"secondaryIdInfos":[{"id":"2019-A02502-55","type":"OTHER","domain":"ID-RCB number,ANSM"}],"organization":{"fullName":"University Hospital, Lille","class":"OTHER"},"briefTitle":"Influence of Cerebral Oedema in Intracerebral Haemorrhage","officialTitle":"Consequences of Oedema on the Prognosis of InTraCerebral Haemorrhage","acronym":"COPITCH"},"statusModule":{"statusVerifiedDate":"2020-11","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-12","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2024-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2020-10-29","studyFirstSubmitQcDate":"2020-11-05","studyFirstPostDateStruct":{"date":"2020-11-09","type":"ACTUAL"},"lastUpdateSubmitDate":"2020-11-05","lastUpdatePostDateStruct":{"date":"2020-11-09","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"University Hospital, Lille","class":"OTHER"},"collaborators":[{"name":"Conseil RÃ©gional Hauts-de-France, France","class":"UNKNOWN"},{"name":"Fondation pour la recherche sur les AVC","class":"UNKNOWN"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"In 2020, IntraCerebral Haemorraghe (ICH) remains the most devastating type of stroke. Besides stroke unit care, no specific treatment has been proven effective yet. Perihaematomal oedema (PHO) could be a promising therapeutic target. However, the mechanisms, the natural history as well as the clinical impact of this PHO remain unclear. The COPITCH study has been designed to answer these questions"},"conditionsModule":{"conditions":["Stroke","Intra Cerebral Hemorrhage"],"keywords":["Intra Cerebral Hemorrhage","Perihaematomal oedema","MRI","outcome"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":500,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Patient with intracerebral haemorrhage","type":"EXPERIMENTAL","description":"Patients will be screened at admission in the stroke units right after brain MRI demonstrating the presence of blood in the brain parenchyma.","interventionNames":["Radiation: Brain MRI","Biological: Biological biomarkers"]}],"interventions":[{"type":"RADIATION","name":"Brain MRI","description":"Brain MRI will include differents sequences.","armGroupLabels":["Patient with intracerebral haemorrhage"]},{"type":"BIOLOGICAL","name":"Biological biomarkers","description":"Biological biomarkers will include a set of systemic inflammatory markers","armGroupLabels":["Patient with intracerebral haemorrhage"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Poor functional outcome defined as a modified Rankin Scale of 4 or more","timeFrame":"at 3 months"}],"secondaryOutcomes":[{"measure":"overall distribution of the modified Rankin scale at 3- and 12 months","description":"The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.\n\nThe scale runs from 0-6, running from perfect health without symptoms to death.","timeFrame":"at 3 months and 12 months"},{"measure":"Early neurological deterioration defined as more than 4 points on the NIHSS score","description":"The NIHSS score (NIH Stroke Scale) is used to monitor the progression of an ischemic or hemorrhagic stroke. It is rated from 0 to 42 points. Depending on the result, a distinction is made from Minor stroke to Severe stroke","timeFrame":"at 96 hours"},{"measure":"all-cause mortality at 3 and 12 months","timeFrame":"at 3 and 12 months"},{"measure":"Cognitive decline","description":"Cognitive decline defined as a score on MOCA test below 27","timeFrame":"at 3 months, at 12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* With a spontaneous ICH, i.e. non traumatic\n* Admitted within 12 hours of stroke onset. For wake-up strokes, time of last seen well will be considered as stroke onset\n* Patient insured under the French social security\n* Consent form signed\n\nExclusion Criteria:\n\n* Pure intraventricular haemorrhages\n* \"secondary\" ICH: ICH resulting from intracranial vascular malformation, intracranial venous thrombosis, head trauma or tumour; haemorrhagic transformation within an infarct\n* Pre-admission modified Rankin score of 4 or 5\n* Life expectancy of less than 1 year related to comorbidities (end stage cancer, end stage organ failure)\n* Pregnancy or breastfeeding or Women of childbearing age without effective contraception (a pregnancy test will be done)\n* Adults who are deprived of their liberty by judicial or administrative decision\n* Referral from other hospitals\n* Contra-indication to MRI : claustrophobia, ocular metallic foreign bodies (accidental or other) or in a risk area (nervous or vascular system);irremovable implanted medical device (pacemaker, neurostimulator, cochlear implants and others);metallic heart valve (mainly old heart valves) or vascular clips previously implanted on cranial aneurysms; gadolinium allergy\n* No consent form","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Charlotte Cordonnier, MD,PhD","role":"CONTACT","phone":"0320445962","email":"charlotte.cordonnier@chru-lille.fr"}],"overallOfficials":[{"name":"Charlotte Cordonnier, MD,PhD","affiliation":"University Hospital, Lille","role":"PRINCIPAL_INVESTIGATOR"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000002543","term":"Cerebral Hemorrhage"},{"id":"D000006470","term":"Hemorrhage"}],"ancestors":[{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020300","term":"Intracranial Hemorrhages"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M9246","name":"Hemorrhage","asFound":"Hemorrhage","relevance":"HIGH"},{"id":"M5482","name":"Cerebral Hemorrhage","asFound":"Cerebral Hemorrhage","relevance":"HIGH"},{"id":"M7347","name":"Edema","relevance":"LOW"},{"id":"M4896","name":"Brain Edema","relevance":"LOW"},{"id":"M21803","name":"Intracranial Hemorrhages","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]}},"hasResults":false}